Fri, Dec 26, 2014, 9:25 AM EST - U.S. Markets open in 5 mins.

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Mar 20, 2014 9:14 AM Flag

    GHDX announces more data supporting its use

    Genomic Health announces presentation of new data further supporting use of Oncotype DX in Europe; physician survey reveals substantial differences in chemotherapy treatment recommendations (GHDX) :
    Co announced the presentation of multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference, which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Genomic Health announces presentation of new data further supporting use of Oncotype DX in Europe; physician survey reveals substantial differences in chemotherapy treatment recommendations (GHDX) :
      Co announced the presentation of multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference, which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.

    • Genomic Health announces presentation of new data further supporting use of Oncotype DX in Europe; physician survey reveals substantial differences in chemotherapy treatment recommendations (GHDX) :
      Co announced the presentation of multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference, which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting

 
GHDX
32.44Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Gilead Sciences Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Spectrum Pharmaceuticals, Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST